NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
https://doi.org/10.15690/vsp.v13i1.908
Abstract
In the article latest published and presented data on 10- and 13-valent pneumococcal conjugate vaccines (PCV10 and PCV13) efficacy and effectiveness in different regions of the world overview is provided for prognosis of expected effect of Russian infants mass immunization as anti-pneumococcal vaccination has been included into the National immunization program in Russia since January 1, 2014. Based on analyzed data conclusion about PCV10 and PCV13 high effectiveness against invasive pneumococcal diseases (IPD) in 3+1 schedule has been made. PCV10 effectiveness against IPD in 2+1 schedule has been determined as 85,8% (Finland), for PCV13 — 100% (Norway). Serotype-specific effectiveness for IPD has been established for PCV10 only for serotypes 6B and 14, at the same time PCV13 serotype-specific effectiveness in 3+1 and 2+1 schedules has been established not only for PCV7-common serotypes, but for additional serotypes 1, 6А, 7F, 19А. In comparison with PCV7 efficacy and effectiveness against pneumonia and otitis media PCV10 has not shown additional benefits (in COMPAS and FinIP trials), at the same time PCV13 has demonstrated subsequent decreasing and additional effectiveness against these diseases (USA, Israel, France, Uruguay, Argentina, South Africa). Sustained and apparent statistically significant nasopharyngeal carriage reduction and herd effect (decreasing of IPD in non-vaccinated part of the population) have been established only for PCV13 (USA, England and Wales, Israel, France).
About the Authors
O. P. Kovtun
Ural State Medical University, Ekaterinburg
Russian Federation
PhD, Head of Pediatrics and Neonatology Department of the Faculty Training and Retraining, Vice-rector for Scientific Research of Ural State Medical University (USMU), Chief Pediatrician of the Ural Federal Region (UrFR), Director of the Sverdlovsk affiliate of Research Center for Children’s Health RAMS
Russian Federation
PhD, Head of Pediatrics and Neonatology Department of the Faculty Training and Retraining, Vice-rector for Scientific Research of Ural State Medical University (USMU), Chief Pediatrician of the Ural Federal Region (UrFR), Director of the Sverdlovsk affiliate of Research Center for Children’s Health RAMS
V. V. Romanenko
Ural State Medical University, Ekaterinburg
Russian Federation
Russian Federation
References
1. World Health Organization. Pneumococcal conjugated vaccine for childhood immunization = WHO position paper. Weekly Epidemiol. Rec. 2007; 7: 93–104.
2. World Health Organization. Pneumococcal conjugated vaccines = WHO position paper. Weekly Epidemiol. Rec. 2012; 14: 129–144.
3. Mc'Intosh D.G., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Exp. Rev. Vaccines. 2011; 10 (1): 109–129.
4. Feikin D.R., Kagucia E.W., Loo J.D., Link-Gelles R., Puhan M.A. et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: A pooled analysis of multiple surveillance sites. PLoS Med. 2013; 10 (9): e1001517. Doi:10.1371/journal.pmed.1001517
5. Briko N.I. Epidemiol. i infekts. bol. Akt. vopr. = Epidemiology and infectious diseases. Current Items. 2013; 6: 4–9.
6. Reinert R.R., Taysi B. Effectiveness of the 13-valent pneumococcal conjugate vaccine: Emerging data from invasive pneumococcal diseases, pneumonia, acute otitis media and nasopharyngeal carriage. Pediatric Pharmacol. 2012; 9 (3): 7–12.
7. Federal'nyi zakon ot 21.12.2013 № 368-FZ «O vnesenii izmeneniya v stat'yu 9 Federal'nogo zakona «Ob immunoprofilaktike infektsionnykh boleznei» [The Federal Law № 368-FZ "On Amendments to Article 9 of the Federal Law "On Immunoprophylaxis of Infectious Diseases" dated 12. 21.2013]. Moscow, 2013.
8. Vopr. sovr. pediatrii = Current pediatrics. 2012; 11 (4): 68–69.
9. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Instruktsiya po primeneniyu Prevenar 13 (vaktsina pnevmokokkovaya kon"yugirovannaya adsorbirovannaya 13-valentnaya) ot 12.07.2012, LP 000798-120712 (2012) [The Ministry of Health of the Russian Federation. Instructions for Application of Prevenar 13 (Pneumococcal Conjugate Vaccine Adsorbed 13-valent) dated 07. 12.2012, LP 000798-120712 (2012)].
10. Ministerstvo zdravookhraneniya Rossiiskoi Federatsii. Instruktsiya po primeneniyu lekarstvennogo preparata dlya meditsinskogo primeneniya Sinfloriks LP 001412-110112 [The Ministry of Health of the Russian Federation. Instructions for for Application of the Drug for Medical Use Sinfloriks LP 001412-110112].
11. Pilishvili T., Lexau C, Farley M, Hadler J, Harrisson L, Bennet N. et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 2010; 201 (1): 32–41.
12. Alyabyeva N.M., Mayanskiy N.A., Ponomarenko O., Katosova L.K., Kulichenko T.V., Namazova-Baranova L.S. Serotype distribution and antibiotic resistance of Streptococcus pneumoniae isolated from children with acute otitis media in Russia, in ESPID2012. Thessaloniki, Greece. 2012.
13. Savinova T.A., Sidorenko S.V. Prognosis of antipneumococcal vaccination application to control the spread of resistance among pneumococci in Russia. Antibiotics and Chemotherapy. 2011; 56: 2–10.
14. Mayanskiy N.A., Alyabyeva N.M., Lazareva A.V., Ponomarenko O., Katosova L.G., Ivanenko A.I., Kulichenko T.V., Namazova-Baranova L.S. Nasopharyngeal carriage of Streptococcus pneumoniae in children with acute bacterial infection in Russia, in ESPID 2012. Thessaloniki, Greece. 2012.
15. Koroleva I.S., Beloshitskiy G.V. Epidemiological characteristics of pneumococcal meningitis in children aged under 6 years of age in the Russian Federation. Epidemiol. Infect. Dis. Comprehensive iss. 2012; 1: 18–21.
16. Simell B., Auranen K., Kayhty H., Goldblatt D., Dagan R., O'Brien K.L. The fundamental link between pneumococcal carriage and disease. Exp. Rev. Vaccines. 2012; 11 (7): 841–855.
17. Foster D., Knox K., Walker A.S., Griffiths D.T., Moore H., Haworth E. et al. Reduction in invasive pneumococcal disease following implementation of the conjugate vaccine in the Oxfordshire region. Engl. J. Med. Microbiol. 2011; 60 (Pt. 1): 91–97.
18. Miller E., Andrews N.J., Waight P.A., Slack M.P.E, George R.C. PCV13 Effectiveness using the indirect cohort method in England and Wales. Vaccine. 2011; 29: 9127–9131.
19. European Medicines Agency. Assessment Report for Synflorix, Common Name: Pneumococcal polysaccharide conjugate vaccine (adsorbed). 2009.
20. Chevallier B., Vesikari T., Brzostek J., Knuf M., Bermal N., Jristegui J. et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr. Infect. Dis. J. 2009; 28 (Suppl. 4): 66–76.
21. European Medicines Agency. Summary of product characteristics for Prevenar 13, Pneumococcal polysaccharide conjugate vaccines (13-valent, absorbed). 2013.
22. Kieninger D.M., Kueper K., Steul K., Juergens C., Ahlers N., Baker S., Jansen K.U. et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010; 28 (25): 4192–4203.
23. Yeh S., Gurtman A., Hurley D., Block S., Schwartz R., Patterson S. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010; 126 (3): 493–505.
24. Kaplan S.L., Barson W., Lin P., Romero J., Bradley J., Tan T. et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 2013; 32 (3): 203–207.
25. Health Protection Agency. Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Pneumococcal.
26. Picazo H. et al. Expansion of serotype coverage in the Universal Pediatric Vaccination Calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain. Clin. Vaccine Immunol. 2013; 20 (10): 1524–1530. Available at: http://dx.doi.org/10.1128/CVI.00239-13
27. Palmu A.A., Jokinen J., Barys D., Neiminen H., Ruokokoski E., Siira L., Puumalainen T. et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet. 2013; 381 (9862): 214–222.
28. Jokinen et al. ISPPD. Iguaçu Falls, Brasil. 2012. (poster). Available at: http://www2.kenes.com/ISPPD/Scientific/Documents/FinalAbstractbook.pdf
29. De Wals P., Lefebvre B., Defay F., Deceuninck G., Bouliame N. Invasive pneumococcal diseases in birth cohorts vaccinated with PCV-7 and/or PHiD-CV in the province of Quebec, Canada. Vaccine. 2012; 30 (45): 6416–6420.
30. Lim E., Heffernan H. Invasive pneumococcal disease quarterly report July-September 2012. Available at: https://surv.esr.cri.nz/surveillance/IPD.php
31. New Zealand Public Health Surveillance. Invasive pneumococcal disease in New Zealand. Available at: http://www.surv.esr.cri.nz/surveillance/IPD.php
32. Available at: http://www.pharmac.health.nz/news/item/national-immunisation-schedule
33. Van den Bergh M.R., Spijkerman J., Swinnen K.M., Francois N.A., Pascal T.G., Borys D. et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin. Infect. Dis. 2013; 56 (3): 30–39.
34. Steens A. et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013; 31: 6232–6238.
35. Van der Linden. Effects of three years of immunisation with higher valent pneumococcal conjugate vaccines in German children. ESCMID. 2013. poster eP735.
36. Pneumo-ADIP investigators group in collaboration with World Health Organization. Case definitions for pneumococcal syndromes and other severe bacterial infections. Clin. Infect. Dis. 2009; 48 (Suppl. 2): 197–202.
37. GlaxoSmithKline, Study No.: 109563 (10PN-PD-DIT-028) COMPAS: a phase III study to demonstrate efficacy of GlaxoSmithKline Biologicals’ 10-valent pneumococcal vaccine (GSK1024850A) against Community Acquired Pneumonia and Acute Otitis Media. 2012. Available at: http://www.gsk-clinicalstudyregister.com/result_detail.jsp?protocolId=109563&studyId=4C067737-D005-43ED-9C26-909AC9413566&compound=Pneumococcal+Polysaccharide+Conjugate+Vaccine+(Adsorbed)
38. EMEA. Summary of product characteristics Synflorix. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000973/human_med_001071.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124
39. Afonso E.T., Minamisava R., Bierrenbach A.L., Escalante J.J.C., Alencar A.P., Domingues C.M. et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children. Emerg. Infect. Dis. Brazil. 2013; 19 (4): 589–597.
40. Kilpi T. et al. Effectiveness of the 10-valent pneumococcal vaccine (PhiD-CV10) against hospital-diagnosed pneumonia in infants — FinIP. Adapted from oral presentation 31st Annual Meeting of the European Society for Paediatric Infectious Diseases. ESPID. Milan, Italy. 2013.
41. Ekelund M., Berglund A., Nyman L. Impact of vaccination with 10 and 13-valent pneumococcal vaccines on inpatient pneumonia cases in vaccinated children in Sweden. 8 WSPID. Capetown, South Africa. 2013.
42. Pirez M.C., Algorta G., Cedres A., Sobrero H., Varella A., Giachetto G., Montano A. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr. Infect. Dis. J. 2011; 30 (8): 669–674.
43. Hortal M., Estevan M., Laurani H., Iraola I., Meny M., Paysandu/Salto Study Group. Hospitalized children with pneumonia in Uruguay: Pre and post introduction of 7 and 13-valent pneumococcal conjugated vaccines into the National Immunization Program. Vaccine. 2012; 30 (33): 4934–4938.
44. Pirez M.C. et al. Poster 512: Etiología NAC. XV SLIPE Congress. San Pablo, Brazil. 2013.
45. Angoulvant F., Levy C., Varon E. et al. Poster 254. 31st Annual Meeting of the European Society for Paediatric Infectious Diseases. Milan, Italy. 2013.
46. Gentile A. et al. Introduction of the PCV13 in Argentina: Assessment of effectiveness to prevent consolidated pneumonia in children, presentation. Abstract B-497. ICAAC 2013. Available at: www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=3283&sKey=342fb18d-ad61-4a43-819d-9a70fafd8f0f&cKey=c8e72d3e-64ee-43a3-a2b5-78aa81e80904
47. Kury C.M.H., Vitral C.L., Kury M.M.H., Moraes J.C., Freixo H.O. et al. WSPID. Capetown, South Africa. 2013.
48. Weinberger D.M., Givon-Lavi N., Shemer-Avni Y., Bar-Ziv J., Alonso W.J. et al. Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel. Emerg. Infect. Dis. 2013; 19: 1084–1091. Doi:10.3201/eid1907.121625
49. Fletcher M.A., Fritzell B. Pneumococcal conjugate vaccines and otitis media: an appraisal of the clinical trials. Int. J. Otolaryngol. 2012: 312935.
50. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., Kohl I. et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006; 367 (9512): 740–748.
51. Vesikari T., Forstén A., Seppä I., Puumalainen T., Soininen A., Lommel P., Hezareh M., Moreira M., Borys D., Schuerman L. Effectiveness of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine against acute otitis media. Tampere: ESPID. 2012.
52. Sáez-Llorens X. et al. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein d conjugate vaccine (PHID-CV) against acute otitis media in children in Panama. Poster presentation at the 9th annual International Symposium on Antimicrobial Agents and Resistance. Kuala Lumpur, Malaysia. 2013.
53. Sarasoja I., Jokinen J., Lahdenkari M., Kilpi K., Palmu A. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr. Infect. Dis. J. 2013; 32: 517–520.
54. Dagan R., Givon-Lavi N., Leibovitz E., Greenberg D. Incidence dynamics of culture-proven otitis media 4 years before and 3 years after introduction of pneumococcal conjugate vaccines (PCVs) in Southern Israel. 2012. Poster 508.
55. Dagan R., Greenberg D., Leibovitz E., Raiz S., Givon-Lavi N.. Trends in serotype-specific pneumococcal carriage in children visiting emergency room (PER). Post PCV7 and PCV13 introduction correlate with trends in serotype-specific otitis media incidence (OM). IDSA. 2013. Poster 445.
56. Dagan R. et al. Mixed pneumococcal-nontypeable Haemophilus influenzae otitis media is a distinct clinical entity with unique epidemiologic characteristics and pneumococcal serotype distribution. JID. 2013; 208: 1152–1160.
57. Dagan R., Ben-Shimo S. Antibiotic-resistance in otitis media (OM) in children <2 Years. ICAAC. 2013. Abstract G-1451.
58. Diel M., Laurenz M. Impact of pneumococcal conjugate vaccines on acute otitis media among children in Germany. ESPID. 2013. 997 p.
59. Palmu A.A., Jokinen J. et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. www.thelancet.com/infection. Published online: November 26, 2013. Available at: http://dx.doi.org/10.1016/S1473-3099(13)70338-4
60. Pelton S.I., Pettigrew M.M., Barenkamp S.J., Godfroid F., Grijalva C.G., Leach A. et al. Panel 6: Vaccines. Otolaryngology. Head and Neck Surgery. 2013; 148 (Suppl. 4): 90–101.
61. Bogaert D., de Groot R., Hermans P.W.M. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect. Dis. 2004; 4 (3): 144–154.
62. Millar E.V., Watt J.P., Bronsdon M.A., Dallas J., Reid R. et al. Indirect effect of 7-valent pneumococcal conjugate vaccine on pneumococcal colonization among unvaccinated household members. Clin. Infect. Dis. 2008; 47 (8): 989–996.
63. Sharma D., Baughman W., Holst A., Thomas S., Jackson D., Carvalho M.G., Beall B., Satola S. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr. Infect. Dis. J. 2013; 32 (2): 45–53.
64. Prymula R., Honovcova I., Miroslav S., Kriz P., Motlova J., Lebedova V. et al. Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine. 2013; 31 (16): 2080–2088.
65. Cohen R., Levy C., Bingen E., Koskas M., Nave I., Varon E. Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. Pediatr. Infect. Dis. J. 1997; 16 (6): 555–560.
66. Pichichero M.C., Casey J.R., Center K. Efficacy of PCV13 in prevention of AOM and NP Colonization in children: First year of data from the US. 2012: 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil. 2012.
67. Cohen R., Levy S., Bingen E., Koskas M., Nave I., Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr. Infect. Dis. J. 2012; 31 (3): 297–301.
68. Dagan R.P.S., Juergens C. The efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) additional serotypes on nasopharyngeal colonization: A randomized double-blind pediatric trial. 8th International Symposium on Pneumococci and Pneumococcal Diseases. Iguaçu Falls, Brazil. 2012.
69. Van der Linden M., Perniciaro S.R., Imöhl M. Effects of 4 years of immunization with higher valent pneumococcal conjugate vaccines in German children and adults. Presentation. Abstract G-1452, ICAAC 2013 www.abstractsonline.com/Plan/AbstractPrintView.aspx?mID=3283&sKey=49cb1df8-6999-459f-a478-e23cc2dca2d6&cKey=617c9122-45a6-421c-bf7f-dc9faefdb346
70. Ansaldi F., Florentis D., Canepa P., Ceravolo A., Rapazzo E., Iudici R. et al. Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: Rationale and perspectives for PCV13 implementation. Hum. Vaccines & Immunother. 2013; 9 (3): 614–620.
71. Kozlov R.S., Krekshina O.I., Murav'ev A.A., Mironov K.O., Platonov A.E., Dunaeva E.A., Tatochenko V.K. et al. Klin. mikrobiol i antimikrobn khimioter. = Clinical microbiology and antimicrobial chemotherapy. 2013; 15 (4): 246–257.
72. Baranov A.A., Namazova-Baranova L.S., Mayanskii N.A., Kulichenko T.V., Polunina T.A., Lazareva A.V. et al. Pediatrich. farmakol. = Pediatric pharmacology. 2013; 10 (5): 1–10.
73. Lobzin Yu.V., Sidorenko S.V., Kharit S.M., Belanov S.S., Volkova M.O., Gostev V.V. et al. Infektologiya = Infectology. 2013; 5 (4): 35–41.
Review
For citations:
Kovtun O.P., Romanenko V.V. NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD. Current Pediatrics. 2014;13(1):18-25. (In Russ.) https://doi.org/10.15690/vsp.v13i1.908
Views:
942
Email this article 
